May 30,2007
Sen. Grassley seeks additional information about pricing and marketing of anti-anemia drugs
WASHINGTON --- Sen. Chuck Grassley is asking a leading drug maker to cooperate with his ongoing inquiry into the pricing and marketing of anti-anemia drugs given to kidney and cancer patients and the Food and Drug Administration’s access to data from the drug maker’s studies of such drugs.
The text of the letter Grassley sent today to Johnson & Johnson is below, along with the text of inquiries he made earlier this month and in April of the Food and Drug Administration, Amgen Inc. and the Centers for Medicare and Medicaid Services.
Grassley is Ranking Member of the Senate Committee on Finance.
###
Next Article Previous Article
Recent News
- Wyden Blasts Trump Administration’s Latest Attack on Cheap Renewable Energy
- Wyden, Warren Probe Lutnick Firm’s Potential Conflicts of Interest Related to Massive Tariff Bets
- Wyden Leads Bill to Reverse Trump Cuts at Social Security and Protect Benefits
- Wyden, Durbin, Senate Democrats Slam Social Security for Disabling Lawfully Obtained Social Security Numbers
- Wyden Blasts Trump’s Regressive Tariffs that Took Effect Today